

# CITATION REPORT

List of articles citing

## Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim

DOI: 10.1007/s40259-019-00373-2  
BioDrugs, 2019, 33, 635-645.

**Source:** <https://exaly.com/paper-pdf/72572413/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
7	Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis. <i>BMC Health Services Research</i> , <b>2019</b> , 19, 827	2.9	13
6	Clinical and Regulatory Concerns of Biosimilars: A Review of Literature. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,	4.6	13
5	[Knowledge and perceptions of biosimilar medicines by health professionals in Tunisia]. <i>Annales Pharmaceutiques Francaises</i> , <b>2021</b> ,	1.3	0
4	Febrile neutropenia prophylaxis, G-CSF physician preferences: discrete-choice experiment. <i>BMJ Supportive and Palliative Care</i> , <b>2021</b> ,	2.2	2
3	Stem Cell Collection and Therapeutic Apheresis. <b>2022</b> , 504-518		
2	Perspectives toward biosimilars among oncologists: A Malaysian survey. <i>Journal of Oncology Pharmacy Practice</i> , 107815522211047	1.7	0
1	Pharmacovigilance of Biological Drugs.		